The results demonstrated that patients who switched from interferon beta (IFN
beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in
annualized relapse rates (0.63 to 0.14). In addition, these patients did not
progress significantly in their disability as measured by expanded disability
status scale (EDSS).